Influenza Vaccines for the World

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Wednesday 3rd April 2019

SESSION 6:
INFLUENZA VACCINES DEVELOPMENTS – III
ANTIGEN DESIGN & CHARACTERIZATION

Moderator: Ted Ross (University of Georgia, Athens, Georgia, USA)

‘Re-examining the current polyvalent design of flu vaccines’
Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)

‘The epitope dilution phenomenon: A way to address variable antigens’
Ed Remarque (BPRC, Rijswijk, The Netherlands)

‘VaxArray platform for rapid assessment of hemagglutinin and neuraminidase in influenza vaccines’
Kathy L. Rowlen (InDevR Inc. Boulder, Colorado, USA)

Coffee Break & Posters

SESSION 7:
INFLUENZA VACCINES DEVELOPMENTS – IV
MECHANISMS OF ACTION & CORRELATES OF PROTECTION

Moderator: Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)

‘Impact of age and pre-existing immunity on influenza-specific B cells and induction of enhance antibody breadth following vaccination in humans’
Ted M. Ross (University of Georgia, Athens, Georgia, USA)

‘New approaches to the development of effective influenza vaccines’
Tokiko Watanabe1 and Yoshihiro Kawaoka2 (1 University of Tokyo, Tokyo, Japan; 2 University of Wisconsin, Madison, Wisconsin, USA)

‘Influenza virus infection as well as immunization induces high titre cross-reactive haemagglutinin-specific antibody-dependent phagocytosis (ADP) and monocyte infection-enhancing responses in macaques’
Ed Remarque (BPRC, Rijswijk, The Netherlands)

‘Novel influenza vaccines: Impact on serological analysis and immune correlates’
Otfried Kistner (Senior Consultant, Vienna, Austria)

Lunch Break & Posters

SESSION 8:
INFLUENZA VACCINES DEVELOPMENTS – V
ROUTES OF ADMINISTRATION & ADJUVANTS

Moderator: Ed Remarque (BPRC, Rijiswijk, The Netherlands)

‘Micro array patch: Phase I study with influenza vaccine’
Julian Hickling (Vaxaas, Woolloongabba, Brisbane, Australia)

‘Improved influenza vaccination through infection mimicry using silk microneedles’
Kathryn Kosuda (Vaxess Technologies Inc., Cambridge, Massachusetts, USA)

‘Microneedle skin vaccination of flagellin-M2e fusion protein and inactivated influenza vaccines confers cross protection’
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)

‘Intradermal adjuvants: The future of vaccine enhancement. Clinical trials and insights’
Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)

‘IgA is critical for protection against influenza following mucosal delivery’
Nikita Kolhatkar (VAXART Inc, South San Francisco, California, USA)

Tea Break & Posters

SESSION 9:
CLINICAL DEVELOPMENT OF NEXT-GENERATION INFLUENZA VACCINES

Moderator: Otfried Kistner (Senior Consultant, Vienna, Austria)

‘Novel live M2SR vaccine elicits broadly cross-reactive immune responses in human subjects’
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)

‘Update on the clinical development of a plant-derived quadrivalent virus-like particles influenza vaccine’
Nathalie Landry (Medicago Inc., Quebec City, Quebec, Canada)

‘Flumist / Fluenz vaccine effectiveness and its return to US market’
Helen Bright (MedImmune UK Ltd, Liverpool, UK)

‘A combined universal/seasonal flu vaccine: A protein nanoparticle vaccine that allows rapid manufacturing’
Peter Burkhard (Alpha-O Peptides AG, Riehen, Switzerland)

‘Influenza virus-based vector platform for respiratory mucosal vaccination’
Andrey Vasin, Marina Stukova, Andrey Egorov, Maria Sergeeva, Anna-Polina Shurygina, Kirill Vasilev, Janna Buzitskaya and Katya Romanovskaya-Romanko (Research Institute of Influenza, St. Petersburg, Russia)

 

IVW 2019 Delegates

Login details will be supplied after you have registered for the event.


IVW 2019 Sponsors

  • SPbSRIVS
  • Vaxart
  • Inovio Pharmaceuticals
  • NanoPass
  • Janssen
  • Vaxxas
  • Eurocine Vaccines
  • FluConsult
  • Vismederi
  • Novavax
  • Sanofi Pasteur
  • InDevR
  • isirv
  • APACI
  • hVIVO
  • MedImmune
  • Medicago

IVW 2019 Downloads

IVW 2019 Leaflet

IVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?